авторефераты диссертаций Ѕ≈—ѕЋј“Ќјя Ѕ»ЅЋ»ќ“≈ ј –ќ——»»

 ќЌ‘≈–≈Ќ÷»»,  Ќ»√», ѕќ—ќЅ»я, Ќј”„Ќџ≈ »«ƒјЌ»я

<< √Ћј¬Ќјя
ј√–ќ»Ќ∆≈Ќ≈–»я
ј—“–ќЌќћ»я
Ѕ≈«ќѕј—Ќќ—“№
Ѕ»ќЋќ√»я
«≈ћЋя
»Ќ‘ќ–ћј“» ј
»— ”——“¬ќ¬≈ƒ≈Ќ»≈
»—“ќ–»я
 ”Ћ№“”–ќЋќ√»я
ћјЎ»Ќќ—“–ќ≈Ќ»≈
ћ≈ƒ»÷»Ќј
ћ≈“јЋЋ”–√»я
ћ≈’јЌ» ј
ѕ≈ƒј√ќ√» ј
ѕќЋ»“» ј
ѕ–»Ѕќ–ќ—“–ќ≈Ќ»≈
ѕ–ќƒќ¬ќЋ№—“¬»≈
ѕ—»’ќЋќ√»я
јƒ»ќ“≈’Ќ» ј
≈Ћ№— ќ≈ ’ќ«я…—“¬ќ
ќ÷»ќЋќ√»я
“–ќ»“≈Ћ№—“¬ќ
≈’Ќ»„≈— »≈ Ќј” »
–јЌ—ѕќ–“
ј–ћј÷≈¬“» ј
»«» ј
»«»ќЋќ√»я
»ЋќЋќ√»я
»Ћќ—ќ‘»я
»ћ»я
Ё ќЌќћ» ј
ЁЋ≈ “–ќ“≈’Ќ» ј
ЁЌ≈–√≈“» ј
ё–»—ѕ–”ƒ≈Ќ÷»я
я«џ ќ«ЌјЌ»≈
ј«Ќќ≈
 ќЌ“ј “џ


Pages:     | 1 |   ...   | 3 | 4 ||

Ђ—ј’ј–Ќџ… ƒ»јЅ≈“: диагностика, лечение, профилактика ѕод редакцией академика –јЌ и –јћЌ ».». ƒедова, профессора ћ.¬. Ўестаковой ...ї

-- [ —траница 5 ] --

Vol. 6 (4). Ч P. 280Ц5. Schwarts A.V., Sellmeyer D.E., Vittinghoff E. et al. Thiazolidinedione use and bone loss in older Erdmann E., Wilcox R.G. Weighing up the cardiovascular benefits of thiazolidinedione therapy: diabetic adults // J. Clin. Endocrinol. Metab. Ч 2006. Ч Vol. 91. Ч P. 3349Ц54.

the impact of the increased risk of heart failure // Europ. Heart J. Ч 2008. Ч Vol. 29. Ч Schweizer A. et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c P. 12Ц20. over 1 year in drug-nave patients with type 2 diabetes // Diabet. Med. Ч 2007. Ч Vol. 24. Ч Hawley J.A., Lessard S.J. Exercise training-induced improvements in insulin action // Acta Phy- P. 955Ц961.

siol (Oxf). Ч 2008. Ч Vol. 192 (1). Ч P. 127Ц35. Schweizer ј., Dejager S., Shao Q. et al. Assessing the cardiovascular safety of vildagliptin: a meta Home P.D., Pocock S.J., Beck-Nielsen H. et al. Rosiglitazone evaluated for cardiovascular outcomes analysis of adjudicated cardiovascular and cerebrovascular events from a large phase 3 popu in oral agent combination therapy for type 2 diabetes (RECRD): a multicenter, randomized, lation (abstract 763) // Diabetologia. Ч 2009. Ч Vol. 52 (Suppl. 1). Ч P. S300.

open-label trial. Published online June 5, 2009. doi:10.1016/S0140Ц6736(09)60953Ц3. Shuster J.J., Jones L.S., Salmon D.A. Fixed vs random effects meta-analysis in rare event studies:

http://avandiarecallnews.com/avandia-study-blocked-dr-david-graham-email-fda-margaret- the rosiglitazone link with myocardial infarction and cardiac death // Stat. Med. Ч 2007. Ч hamburg/ (accessed October 24th 2010). Vol. 26. Ч P. 4375Ц85.

470 Ћитература √лава 13. Ћечение сахарного диабета 2 типа Dae-Kyu Song and Frances M. Ashcroft. Glimepiride block of cloned -cell, cardiac and smooth Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone:

a meta-analysis // J.A.M.A. Ч 2007. Ч Vol. 298. Ч P. 1189Ц1195. muscle KATP channels // Brit. J. Pharmacol. Ч 2001.

Singh S., Loke Y.K., Furberg C.D. Thiazolidinediones and heart failure: a teleoanalysis // Diab. Holman R.R., Paul S.K., Bethel M.A. et al. 10-Year Follow-up of Intensive Glucose Control in Type Care. Ч 2007. Ч Vol. 30. Ч P. 2248Ц2254. 2 diabetes // New Engl. J. Med. Ч 2008. Ч Vol. 359. Ч P. 1577Ц1589.

Statement by an American Association of Clinical Endocrinologists/American College of Endo- Jrgensen —.J., Gunnar H., Gislason L. Effects of oral glucose-lowering drugs on long term out crinology Consensus on type 2 diabetes mellitus: an algorithm for glycemic control // End. comes in patients with diabetes mellitus following myocardial infarction not treated with Practice. Ч 2009. Ч Vol. 15 (6). emergent percutaneous coronary intervention Ч a retrospective nationwide cohort study // Tatti P. The rise and fall of rosiglitazone // Clin. Med. Ther. Ч 2009. Ч Vol. 1. Ч P. 313Ц319. Cardiovasc. Diabetol. Ч 2010. Ч Vol. 9. Ч P. 54Ц59.

The BARI 2D Study Group / Frye R.L., August P., Brooks M.M. et al. A randomized trial of Kevin M. Pantalone, Michael W. Kattan risk of overall mortality in patients with type 2 diabe therapies for type 2 diabetes and coronary artery disease // New Engl. J. Med. Ч 2009. Ч tes receiving Glipizide, Glyburide, or Glimepiride monotherapy. A retrospective analysis // Vol. 360. Ч P. 2503Ц15. Diab. Care. Ч 2010. Ч Vol. 33.

The DREAM (Diabetes Reduction Asessment with ramipril and rosiglitasone Medication) Trial Kurukulasuriya R., Sowers J.R. Therapies for type 2 diabetes: lowering HbA1c and associated car Investigators. Effect of rosiglitasone on the frequency of diabetes in patientswith impaired diovascular risk factors // Cardiovasc. Diabetol. Ч 2010. Ч Vol. 9. Ч P. 45Ц55.

glucose tolerance or impaired fasting glucose: a randomized controlled trial // Lancet. Ч Lаngtry H.D., Balfour J.A. Glimepiride. A review of its use in the management of type 2 diabetes 2006. Ч Vol. 368. Ч P. 1096Ц1105. mellitus // Drugs. Ч 1998. Ч Vol. 55 (4). Ч P. 563Ц84.

Ferrannini E. et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients Mannucci E., Monami M., Masotti G., Marchionni N. All-cause mortality in diabetic patients treat with type 2 diabetes mellitus inadequately controlled on metformin monotherapy // Diab. ed with combination of sulfonylureas and biguanides // Diab. Metab. Res. Rev. Ч 2004. Ч Obes. Metab. Ч 2009. Ч Vol. 11. Ч P. 157Ц166. Vol. 20.

Foley J., Hoffmann –., Liguecos-Saylan ћ. et al. Lack of vildagliptin effects on the immune system Meinert C.L., Knatterud G.L., Prout T.E. et al. The University Group Diabetes Program: a study (abstract 773) // Diabetologia. Ч 2009. Ч Vol. 52 (Suppl. 1). Ч P. S304ЦS305. of the effect of hypoglycemic agents on vascular complications in patients with adult-onset Viberti G., Kahn S.E., Green D.A. et al. A Diabetes Outcome Progression Trial (ADOPT): diabetes II. Mortality results // Diab. Ч 1970. Ч Vol. 19 (Suppl. 1). Ч P. 789Ц830.

an internationalmulticenter study of the comparative efficacy ofrosiglitazone, glyburide, Nathan D.M., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type and metformin in recentlydiagnosed type 2 diabetes // Diab. Care. Ч 2002. Ч Vol. 25. Ч diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus P. 1737Ц43. statement of the American Diabetes Association and the European Association for the Study Woodcock J., Sharfstein J.M., Hamburg M. Regulatory action on rosiglitazone by the US Food and of Diabetes // Diab. Care. Ч 2009.

Drug Administration // New Engl. J. Med. Ч 2010;

DOI:10.1056. Nattrass M., Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? // Int. J. Obes. Relat. Metab.

Disord. Ч 2000. Ч Vol. 24 (Suppl. 3). Ч P. S21ЦS31.

  п. 13.3. јметов ј.—., —олу€нова “.Ќ. —овременные подходы к комбинированному лечению сахарного Nordin —. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence // диабета 2 типа // Consilium Medicum. Ч 2007. Ч є 9. Ч C. 16Ц20. Rev. Diabetol. Ч 2010. Ч Vol. 53 (8).

«илов ј.¬., “ерехова ј. ѕрепараты сульфонилмочевины в лечении сахарного диабета // Pantalone K.M., Kattan M.W., Yu C. The risk of overall mortality in patients with type 2 dia ¬рач. Ч 2008. Ч є 11. Ч C. 28Ц32. betes receiving glipizide, glyburide, or glimepiride monotherapy // Diab. Care. Ч 2010. Ч Ўестакова ћ.¬. ¬ыбор безопасной сахароснижающей терапии при поражении почек Vol. 33. Ч P. 1224Ц1229.

у больных сахарным диабетом // Consilium Medicum. Ч 2009. Ч є 12. Ч 34Ц39. Proks P. Sulfonylurea Stimulation of Insulin Secretion // Diab. Ч 2007. Ч Vol. 51.

Asghar O., Al-Sunni A., Khavandi K. et al. Diabetic cardiomyopathy // Clin. Sci. (Lond.). Ч Renier G., Mamputu J.C., Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in 2009. Ч Vol. 116 (Pt. 10). Ч P. 741Ц760. monocyte adhesion to endothelial cells // Metabolism. Ч 2003. Ч P. 52Ц63.

Culy C.R., Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus // Riddle M.C. Sulfonylureas Differ in Effects on Ischemic Preconditioning Ч Is it Time to Retire Drugs. Ч 2001. Ч Vol. 61(11). Ч P. 1625Ц60. Glyburide? // J. Clin. Endocrinol. Metab. Ч 2003. Ч Vol. 88.

Dhindsa P., Davis K.L., Donnelly R. Comparison of the micro- and macro-vascular effects of Rodbard H.W., Jellinger P.S. The American Association of Clinical Endocrinologists/American glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double- College of Endocrinology (AACE/ACE) algorithm for managing glycaemia in patients with blind, crossover study // Brit. J. Clin. Pharmacol. Ч 2003. Ч Vol. 55 (6). Ч P. 616Ц619. type 2 diabetes mellitus: comparison with the ADA/EASD algorithm // Diabetologia. Ч Eurich D.T., McAlister F.A., Blackburn D.F. et al. Benefits and harms of antidiabetic agents 2010. Ч Vol. 53 (11).

in patients with diabetes and heart failure: systematic review // Brit. Med. J. Ч 2007. Ч Tentolouris N., Voulgari C. A review of nateglinide in the management of patients with type Vol. 335. Ч P. 497. diabetes // Vasc. Health Risk Manag. Ч 2007. Ч Vol. 3 (6). Ч P. 797Ц807.

Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis of hypoglyc- Tzoulaki I., Molokhia M., Curcin V. et al. Risk of cardiovascular disease and all cause mortality emia and cardiovascular events: a comparison of glyburide with other secretagogues and with among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort insulin // Diab. Care. Ч 2007. Ч Vol. 30 (2). Ч P. 389Ц94. study using UK general practice research database // B.M.J. Ч 2009. Ч Vol. 339.

Geisen K. Cardiovascular effects of conventional sulphonylureas and glimepiride // Horm. Metab. Yamanouchi T., Sakai T., Igarashi K. et al. Comparison of metabolic effects of pioglitazone, met Res. Ч 1996. formin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabe Giblin J.P. The Molecular Assembly of ATP-sensitive Potassium Channels // J. Biol. Chem. Ч 1999. tes // Diabet Med. Ч 2005. Ч Vol. 22. Ч P. 980Ц985.

472 √лава 13. Ћечение сахарного диабета 2 типа Ћитература Kim D., MacConell L., Zhuang D. et al. Effects of once-weekly dosing of a long-acting release for   п. 13.3. ƒедов ».»., Ўестакова ћ.¬. »нкретины Ч нова€ веха в лечении сахарного диабета 2 типа. Ч mulation of exenatide on glucose control and body weight in subjects with type 2 diabetes // ћ.: ƒипак, 2010. Ч 92 с. Diab. Care. Ч 2007. Ч Vol. 30. Ч P. 1487Ц93.

Barnett A.H., Burger J., Johns D. et al. Tolerability and efficacy of exenatide and titrated insulin Kirby M.S., Dorso C., Wang A. et al. In vitro enzy-mologic characteristics of saxagliptin, a highly glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or potent and selective DPP4 inhibitor with Ђslow bindingї characteristic (abstract) // Clin.

a sulfonylurea: a multinational, randomized, open-label, two-period crossover noninferiority Chem. Lab. Med. Ч 2008. Ч Vol. 46. Ч P. A29.

trial // Clinical. Therapeutics. Ч 2007. Ч Vol. 29. Ч P. 2333Ц2348. Kolterman O., Kim D.D., Shen L. et al. Pharmacokinetics, pharmacodynamics, and safety of ex Blonde L., Klein E.J., Han J. et al. Interim analysis of the effects of exenatide treatment on A1C, enatide in patients with type 2 diabetes mellitus // Amer. J. Health Syst. Pharm. Ч 2005. Ч weight and cardiovascular risk factors over 82 weeks in 314 patients with type 2 diabetes // Vol. 62. Ч P. 173Ц181.

Diab. Obes. Metab. Ч 2006. Ч Vol. 8. Ч P. 436Ц47. Marre M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over Bosi E., Camisasca R.P., Collober C. et al. Effects of vildagliptin on glucose control over 24 weeks 26 weeks produces greater improvements in glycaemic and weight control compared with in patients with type 2 diabetes inadequately controlled with metformin // Diab. Care. Ч adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) // Diab.

2007. Ч Vol. 30. Ч P. 890Ц895. Medicine. Ч 2009. Ч P. 268Ц278.

Buse J. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week Matveyenko A.V., Dry S., Cox H.I. et al. Beneficial endocrine but adverse exocrine effects of si randomised, parallel-group, multinational, open-label trial (LEAD-6) // Lancet. Ч 2009. Ч tagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes:

Vol. 47. Ч P. 374Ц39. interactions with metformin // Diab. Ч 2009. Ч Vol. 58 (7). Ч P. 1604Ц15.

Davis S.N., Johns D., Maggs D. et al. Exploring the substitution of exenatide for insulin in patients Nauck M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in treated with insulin in combination with oral antidiabetes agents // Diab. Care. Ч 2007. Ч combination with metformin in type 2 diabetes mellitus (LEAD-2 Met) // Diab. Care. Ч Vol. 30. Ч P. 2767Ц72. 2009. Ч Vol. 32. Ч P. 84Ц90.

Deacon C.F., Carr R.D., Holst J.J. DPP-4 inhibitor therapy: new directions in the treatment of Nauck M. et al. LEAD-5 // Diab. Ч 2008. Ч Vol. 57 (Suppl. 1). Ч P. A150, A4.

type 2 diabetes // Front Biosci. Ч 2008. Ч Vol. 13. Ч P. 1780Ц1794. Nauck M.A. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared Debora Williams-Herman, Elizabeth Round, Arlene S. Swern et al. Safety and tolerability of si- with the sulfonylurea, glipizide, in patients with Type 2 diabetes inadequately controlled tagliptin in patients with type 2 diabetes: a pooled analysis. Merck Research Laboratories, on metformin alone: a randomized, double-blind, non-inferiority trial // Diab. Obes. Me Rahway, NJ, USA // BMC Endocrine Disorders. Ч 2008. Ч Vol. 8. Ч P. 14 doi:10.1186/ tab. Ч 2007. Ч Vol. 9 (2). Ч P. 194Ц205.

1472-6823-8-14.

Pi-Sunyer F.X., Schweizer A., Mills D. et al. Efficacy and tolerability of vildagliptin monotherapy DeFronzo R.A., Hissa M.N., Garber A.J. et al. The efficacy and safety of saxagliptin when added in drug-nave patients with type 2 diabetes // Diab. Res. Clin. Pract. Ч 2007. Ч Vol. 76. Ч to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin P. 132Ц138.

alone // Diab. Care. Ч 2009. Ч Vol. 32 (9). Ч P. 1649Ц1655.

Rosenstock J., Baron M.A., Dejager S. et al. Comparison of vildagliptin and rosiglitazone mono Dhillon S., Weber J. Saxagliptin // Drugs. Ч 2009. Ч Vol. 69 (15). Ч P. 2103Ц2114.

therapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial // Diab.

Fehse F.C., Trautmann M.E., Holst J.J. et al. Exenatide augments first- and second-phase insulin Care. Ч 2007. Ч Vol. 30. Ч P. 217Ц223.

secretion in response to intravenous glucose in subjects with type 2 diabetes // J. Clin. En Rosenstock J., Aguilar-Salinas C., Klein E. et al. Effect of saxagliptin monotherapy in treatment docrinol. Metab. Ч 2005. Ч Vol. 90. Ч P. 5991Ц5997.

naive patients with type 2 diabetes // Curr. Med. Res. Opin. Ч 2009. Ч Vol. 25 (10). Ч Fonseca V., Schweizer A., Albrecht D. et al. Addition of vildagliptin to insulin improves glycaemic P. 2401Ц2411.

control in type 2 diabetes // Diabetologia. Ч 2007. Ч Vol. 50. Ч P. 1148Ц1155.

Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor Fura A., Khanna A., Vyas V. et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in drug-nave patients with type 2 diabetes // Diab. Obes. Metab. Ч 2008. Ч saxagliptin in rats, dogs, and monkeys and clinical projections // Drug. Metab. Dispos. Ч Vol. 10 (5). Ч P. 376Ц386.

2009. Ч Vol. 37 (6). Ч P. 1164Ц1171.

Russell-Jones D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin Garber A., Henry R., Ratner R. et al. LEAD-3 (Mono) Study Group. Liraglutid versus glimepiride and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD- monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double met + SU) // Diabetologia. Ч 2009. Ч Vol. 52. Ч P. 2046Ц2053.

blind, parallel-treatment trial // Lancet. Ч 2009. Ч Vol. 373. Ч P. 473Ц481.

Schweizer A., Couturier A., Foley J.E., Dejager S. Comparison between vildagliptin and metformin Garber A.J., Foley J., Banerji M.A. et al. Effects of vildagliptin on glucose control in patients with to sustain reductions in HbA1c over 1 year in drug-nave patients with type 2 diabetes // type 2 diabetes inadequately controlled with a sulfonylurea // Diab. Obes. Metab. Ч 2008. Ч Diab. Med. Ч 2007. Ч Vol. 24. Ч P. 955Ц961.

Vol. 10 (11). Ч P. 1047Ц56.

Zinman B. et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with Goldstein B.J. et al. Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Pepti metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met + TZD) // dase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 diabetes // Diab. Care. Ч 2009. Ч Vol. 32. Ч P. 1224Ц1230.

Diab. Care. Ч 2007. Ч Vol. 30. Ч P. 1979Ц1987.

Hermansen K. et al. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl pepti   п. 13.3. dase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately control „азова ».≈., ћычка ¬.Ѕ. Ћечение метаболического синдрома: фокус на акарбозу //  ардио led on glimepiride alone or on glimepiride and metformin // Diab. Obes. Metab. Ч 2007. Ч васк. тер. и профилакт. Ч 2008. Ч є 7 (2). Ч —. 12Ц20.

Vol. 9(5). Ч P. 733Ц745.

474 √лава 13. Ћечение сахарного диабета 2 типа Ћитература Catalan V.S., Couture J.A., LeLorier J. Predictors of persistence of use of the novel antidiabetic Hoogwerf B.J. Does intensive therapy of type 2 diabetes help or harm? Seeking accord on agent acarbose // Arch. Intern. Med. Ч 2001. Ч Vol. 161. Ч P. 1106. ACCORD // Cleveland Clin. J. Med. Ч 2008. Ч Vol. 75(10). Ч P. 729Ц737.

Chiasson J. The STOP-NIDDM trial. An international study on efficacy of an -glucosidase How to initiate, titrate, and intensify insulin treatment in type 2 diabetes // US Pharm. Ч 2007. Ч inhibitor to prevent type 2 diabetes in a population with IGT // Diab. Care. Ч 1998. Ч Vol. 32(10). Ч P. 10Ц16.

Vol. 21. Ч P. 1720. International Diabetes Federation. Guideline for management of postmeal glucose, 2007.

Chiasson J.L., Josse R.G., Gomis R. et al. Acarbose treatment and the risk of cardiovascular disease Medical Platform, Top-level Titration Guidelines Final version 3, 2008.

and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial // Mooradian A.D., Bernbaum M., Albert S.G. Narrative Review: A Rational Approach to Starting J.A.M.A. Ч 2003. Ч Vol. 290. Ч P. 486. Insulin Therapy // Ann. Intern. Med. Ч 2006. Ч Vol. 145. Ч P. 125Ц134.

Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or pla- Nathan D.M. Finding new treatments for diabetes Ч how many, how fast Е how good? // New cebo in dietary-treated NIDDM patients: the Essen-II Study // Amer. J. Med. Ч 1997. Ч Engl. J. Med. Ч 2007. Ч Vol. 356. Ч P. 437Ц440.


Vol. 103. Ч P. 483. Nathan D.M., Ferrannini E., Holman R.R. et al. Medical management of hyperglycaemia in type van de Laar F.A., Lucassen P.L., Akkermans R.P. et al. Alpha-glucosidase inhibitors for patients 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy // with type 2 diabetes: results from a Cochrane systematic review and meta-analysis // Diab. Diabetologia. Ч 2009. Ч Vol. 52. Ч P. 17Ц30.

Care. Ч 2005. Ч Vol. 28. Ч P. 154. Philis-Tsimikas A. et al. Study 1632. A comparison of once-daily insulin detemir with NPH in sulin when added to oral antidiabetic drags in poorly controlled type 2 diabetes // Clin.

Ther. Ч 2006. Ч Vol. 28. Ч P. 1569Ц1581.

  п. 13.3. јлгоритмы специализированной медицинской помощи больным сахарным диабетом / ѕод Raskin P. et al. Initiating insulin therapy in type 2 diabetes // Diab. Care. Ч 2005. Ч Vol. 28. Ч ред. ».». ƒедова, ћ.¬. Ўестаковой. Ч 4-е изд. Ч ћ., 2009. Ч 103 с. P. 260Ц265.

ƒедов ».»., Ўестакова ћ.¬. ќптимизаци€ и интенсификаци€ инсулинотерапии при —ƒ 2: Raskin P.R., Hollander P.A., Lewin A. et al. On behalf of the INITIATE Study Group. Basal in  лин. рекоменд. // —ах. диабет: —пецвып. Ч 2010. Ч —. 9Ц16. sulin or premix analogue therapy in type 2 diabetes patients // Europ. J. Intern. Med. Ч A Position Statement of the American Diabetes Association and a Scientific Statement of the 2007. Ч Vol. 18. Ч P. 56Ц62.

American College of Cardiology Foundation and the American Heart Association // J. Amer. Ret J. et al. Patients with type 2 diabetes can achieve A1C targets with once-daily biphasic insulin College of Cardiol. Ч 2009. Ч Vol. 53 (3). aspart 70/30 (NovoLog Mix 70/30) before supper // Diab. Ч 2004. Ч Vol. 53 (Suppl. 2). Ч American Association of Clinical Endocrinologists. American Association of Clinical Endocrinolo- P. A130.

gists medical guidelines for clinical practice for the management of diabetes mellitus // En- Robertson C. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose docr. Pract. Ч 2007. Ч Vol. 13 (Suppl. 1). Ч P. 1Ц68. control // Diab. Educ. Ч 2006. Ч Vol. 32. Ч P. 423Ц432.

American Diabetes Association. Standards of medical care in diabetes // Diab. Care. Ч 2009. Ч Rodbard H.W., Jellinger P.S., Davidson J.A. et al. Statement by an American Association of Clinical Vol. 32 (Suppl. 1). Ч P. S13ЦS61. Endocrinologists / American College of Endocrinology Consensus Panel on Type 2 Diabe Brunton S.A., Davis S.N., Renda S.M. Early intervention to achieve optimal outcomes in type tes Mellitus: An Algorithm for Glycemic Control // Endocr. Pract. Ч 2009. Ч Vol. 15(6). Ч 2 diabetes: a case presentation // Clin. Cornerstone. Ч 2006. Ч Vol. 8 (Suppl. 2). Ч P. S6Ц P. 541Ц559.

S18. Rosenstock J. et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with Canadian Diabetes Association. 2008 Clinical Practice Guidelines for the prevention and man- insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive agement of diabetes in Canada // Can. Diab. Ч 2008. Ч Vol. 32 (1). Ч P. S1ЦS201. people with type 2 diabetes // Diabetologia. Ч 2008. Ч Vol. 51. Ч P. 408Ц416.

Cefalu W.T. Glycemic Targets and Cardiovascular Disease // New Engl. J. Med. Ч 2008. Ч Skyler J.S., Bergenstal R., Bonow R.O. et al. Intensive glycemic control and the prevention of Vol. 358. Ч P. 2633Ц5. cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes Trials // Gerstein H.C., Miller M.E., Byington R.P. et al. Effects of intensive glucose lowering in type 2 Diab. Care. Ч 2009. Ч Vol. 32. Ч P. 187Ц192.

diabetes // New Engl. J. Med. Ч 2008. Ч Vol. 358. Ч P. 2545Ц2559. Tamas et al. // Diab. Res. Clin. Pract. Ч 2001. Ч Vol. 54. Ч P. 105Ц14.


Guidelines on diabetes, prediabetes and cardiovascular disease. The Task Force on diabetes and The Action to Control Cardiovascular Risk in Diabetes Study Group / Gerstein H.C., Miller M.E., cardiovascular disease of the European Society of Cardiology (ESC) and the European Byington R.P. et al. Effects of intensive glucose lowering in type 2 diabetes // New Engl. J.

Association for the Study of Diabetes (EASD) // Europ. Heart J. Suppl. Ч 2007. Ч Vol. 9 Med. Ч 2008. Ч Vol. 358. Ч P. 2545Ц59.

(Suppl. C). Ч P. C3ЦC74. The ADVANCE Collaborative Group / Patel A., MacMahon S., Chalmers J. et al. Intensive blood Hermansen K. et al. A 26-week, randomized, parallel, treat-to-target trial comparing Insulin De- glucose control and vascular outcomes in patients with type 2 diabetes // New Engl. J.

temir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive Med. Ч 2008. Ч Vol. 358. Ч P. 2560Ц72.

people with type 2 diabetes // Diab. Care. Ч 2006. Ч Vol. 29. Ч P. 1269Ц1274.

Holman R.R., Paul S.K., Bethel M.A. et al. 10-year follow-up of intensive glucose control in type 2   п. 13. diabetes // New Engl. J. Med. Ч 2008. Ч Vol. 359. Ч P. 1577Ц89. јлгоритмы специализированной медицинской помощи больным сахарным диабетом / ѕод Holman R.R., Thorne K.I., Farmer A.J. et al. 4-T Study Group. Addition of biphasic, prandial, or ред. ».». ƒедова, ћ.¬. Ўестаковой. Ч 4-е изд., доп. Ч ћ., 2009.

basal insulin to oral therapy in type 2 diabetes // New Engl. J. Med. Ч 2007. Ч Vol. 357. Ч ƒедов ».»., Ўестакова ћ.¬. ќптимизаци€ и интенсификаци€ инсулинотерапии при —ƒ P. 1716Ц30. (клинические рекомендации) // —ах. диабет: —пецвып. Ч 2010. Ч —. 9Ц16.

√лава 13. Ћечение сахарного диабета 2 типа Duckworth W., Abraira C., Moritz T. et al. (VADT Investigators). Glucose control and vascular √лава ѕ–ќ‘»Ћј “» ј complications in veterans with type 2 diabetes (published correction appears in N. Engl. J.

Med. 2009. Ч Vol. 361. Ч P. 1024Ц1025, 1028) // New Engl. J. Med. Ч 2009. Ч Vol. 360. Ч —ј’ј–Ќќ√ќ ƒ»јЅ≈“ј 2 “»ѕј P. 129Ц139.

Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis of hypoglyc emia and cardiovascular events: a comparison of glyburide with other secretagogues and with ќ.ё. —ухарева, ћ.¬. Ўестакова insulin // Diab. Care. Ч 2007. Ч Vol. 30. Ч P. 389Ц394.

Miller M.E., Byington R.P., Goff D.C. Jr. et al. (Action to Control Cardiovascular Risk in Diabe tes Study Group). Effects of intensive glucose lowering in type 2 diabetes // New Engl. J.

Med. Ч 2008. Ч Vol. 358. Ч P. 2545Ц2559.

Mu J., Woods J., Zhou Y.P. et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic -cell mass and function in a rodent model of type 2 diabetes // Diab. Ч 2006. Ч Vol. 55. Ч P. 1695Ц1704.

Nathan D.M., Buse J.B., Davidson M.B. et al. American Diabetes Association;

European Asso ciation for the Study of diabetes Medical management of hyperglycemia in type 2 diabetes:

a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of diabe tes // Diab. Care. Ч 2009. Ч Vol. 32. Ч P. 193Ц203.

Nathan D.M., Buse J.B., Davidson M.B. Management of hyperglycemia in type 2 diabetes: a con ¬ о второй половине ’’ и начале ’’I в. стремительный рост научных sensus algorithm for the initiation and adjustment of therapy. A consensus statement from достижений, внедрение новых технологий во все сферы жизни и до the American Diabetes Association and the European Association for the Study of Diabe ступность благ цивилизации породили новую эпидемию, угрожающую tes // Diab. Care. Ч 2006. Ч Vol. 29. Ч P. 1963Ц1972.

благополучию человечества. ¬ современных услови€х урбанизации, что со Patel A., MacMahon S., Chalmers J. et al. (ADVANCE Collaborative Group). Intensive blood glu cose control and vascular outcomes in patients with type 2 diabetes // New Engl. J. Med. Ч провождаетс€ избыточным питанием, включа€ пресловутый Ђфастфудї, ми 2008. Ч Vol. 358. Ч P. 2560Ц2572. нимизацией двигательной активности и хроническим стрессом, стремительно Pospisilik J.A., Martin J., Doty T. et al. Dipeptidyl peptidase IV inhibitor treatment stimulates нарастает распространенность ожирени€ и сахарного диабета, тесно св€занных beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats // Diab. Ч между собой. ќтражением этих взаимосв€занных процессов стало по€вление 2003. Ч Vol. 52 (3). Ч P. 741Ц50.

термина ЂDiabesityї (от ЂDiabetes + Obesityї, Ђƒиабет + ќжирениеї).

Rodbard H.W., Jellinger P.S., Davidson J.A. еt al. Statement by an American Association of Clinical “емпы роста заболеваемости диабетом уже давно прин€ли угрожающий Endocrinologists / American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control // Endocr. Pract. Ч 2009. Ч Vol. 15 (6). Ч характер эпидемического бедстви€ и поставили сахарный диабет в один р€д P. 540Ц559. с традиционно вызывающими страх заболевани€ми Ч мал€рией, туберкулезом, Sturis J., Gotfredsden C.F., Romer J. et al. GLP-1 derivative liraglutide in rats with beta-cell de —ѕ»ƒом, что нашло свое отражение в прин€тии 20 декабр€ 2006 г. резолюции ficiencies: influence of metabolic state on beta-cell mass dynamics // Brit. J. Pharmacol. Ч ќќЌ 61/225, призывающей все страны мира объединитьс€ перед лицом над 2003. Ч Vol. 140. Ч P. 123Ц132.

вигающейс€ угрозы.

Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replica —ахарный диабет типа 2 составл€ет до 90% всех случаев диабета. Ёксперты tion and neogenesis, resulting in increasing beta-cell mass and improved glucose tolerance in ћеждународной диабетической федерации прогнозируют, что в мире число diabetic rats // Diab. Ч 1999. Ч Vol. 48. Ч P. 2270Ц76.

больных —ƒ с 285 млн человек в 2010 г. (6,6% населени€) к 2030 г. увеличитс€ до 438 млн человек, что составит 7,8% населени€. “акже увеличитс€ и число лиц с предиабетом (нарушенной гликемией натощак и нарушенной толерант ностью к глюкозе) Ч с 344 млн в 2010 г. до 472 млн к 2030 г. (с 7,9 до 8,4% по пул€ции).

¬ –оссийской ‘едерации, по данным √осударственного регистра, сахар ным диабетом страдают 3 млн 121 тыс. человек. — учетом того что при —ƒ 2 на каждый диагностированный случай заболевани€ приходитс€ как минимум два недиагностированных, то реальное число больных в –‘ соответствует 8Ц9 млн человек.

Ќаучное издание —ј’ј–Ќџ… ƒ»јЅ≈“:

диагностика, лечение, профилактика ѕод редакцией академика –јЌ и –јћЌ ».». ƒедова, профессора ћ.¬. Ўестаковой √лавный редактор ј.—. ѕетров ќтветственный за выпуск ќ.ё. –ум€нцева —анитарно-эпидемиологическое заключение є 77.99.60.953.ƒ.008014.07.09 от 08.07.2009 г.

ѕодписано в печать 28.07.11. ‘ормат 70 100/16.

Ѕумага офсетна€. ѕечать офсетна€. √арнитура ЂPetersburgї.

ќбъем 50,5 печ. л. “ираж экз. «аказ є.

ќќќ Ђ»здательство Ђћедицинское информационное агентствої

119048, ћосква, ул. ”сачева, д. 62, стр. 1, оф. “ел./факс: (499)245-45- е-mail: miapubl@mail.ru;

http://www.medagency.ru »нтернет-магазин: www.medkniga.ru  нига почтой на ”краине: а/€ 4539, г. ¬инница, E-mail: maxbooks@svitonline.com “елефоны: +380688347389, 8(0432)

Pages:     | 1 |   ...   | 3 | 4 ||
 





 
© 2013 www.libed.ru - ЂЅесплатна€ библиотека научно-практических конференцийї

ћатериалы этого сайта размещены дл€ ознакомлени€, все права принадлежат их авторам.
≈сли ¬ы не согласны с тем, что ¬аш материал размещЄн на этом сайте, пожалуйста, напишите нам, мы в течении 1-2 рабочих дней удалим его.